PT3137073T - Inibidores do glyt1 para utilização no tratamento de distúrbios hematológicos - Google Patents

Inibidores do glyt1 para utilização no tratamento de distúrbios hematológicos

Info

Publication number
PT3137073T
PT3137073T PT157179169T PT15717916T PT3137073T PT 3137073 T PT3137073 T PT 3137073T PT 157179169 T PT157179169 T PT 157179169T PT 15717916 T PT15717916 T PT 15717916T PT 3137073 T PT3137073 T PT 3137073T
Authority
PT
Portugal
Prior art keywords
treatment
hematological disorders
glyt1 inhibitors
glyt1
inhibitors
Prior art date
Application number
PT157179169T
Other languages
English (en)
Inventor
Alberati Daniela
Koerner Annette
Pinard Emmanuel
Winter Michael
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT3137073T publication Critical patent/PT3137073T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT157179169T 2014-04-30 2015-04-27 Inibidores do glyt1 para utilização no tratamento de distúrbios hematológicos PT3137073T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14166497 2014-04-30

Publications (1)

Publication Number Publication Date
PT3137073T true PT3137073T (pt) 2018-07-27

Family

ID=50677958

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157179169T PT3137073T (pt) 2014-04-30 2015-04-27 Inibidores do glyt1 para utilização no tratamento de distúrbios hematológicos

Country Status (18)

Country Link
US (1) US9877963B2 (pt)
EP (1) EP3137073B1 (pt)
JP (1) JP6283766B2 (pt)
KR (1) KR101869185B1 (pt)
CN (1) CN106163520B (pt)
AR (1) AR100209A1 (pt)
CY (1) CY1120508T1 (pt)
ES (1) ES2683184T3 (pt)
HR (1) HRP20181205T1 (pt)
MA (1) MA39927B1 (pt)
MY (1) MY189930A (pt)
PH (1) PH12016501784A1 (pt)
PT (1) PT3137073T (pt)
RS (1) RS57535B1 (pt)
SG (2) SG11201608397UA (pt)
SI (1) SI3137073T1 (pt)
TR (1) TR201809598T4 (pt)
WO (1) WO2015165842A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3199156A1 (de) * 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
CU20200106A7 (es) * 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2021142329A1 (en) * 2020-01-09 2021-07-15 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
KR20230169982A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 리보솜 장애와 관련된 빈혈을 치료하기 위한 조성물 및 방법
CA3220137A1 (en) * 2021-05-14 2022-11-17 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
AU2022283357A1 (en) * 2021-05-27 2023-12-07 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin
WO2023235326A1 (en) * 2022-05-31 2023-12-07 Disc Medicine, Inc. Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4252598B2 (ja) * 2003-08-11 2009-04-08 エフ.ホフマン−ラ ロシュ アーゲー Or置換フェニル基を有するピペラジン及びglyt1阻害剤としてのこれらの使用
KR100928599B1 (ko) * 2005-02-07 2009-11-26 에프. 호프만-라 로슈 아게 글라이신 트랜스포터 1의 저해제로서의 헤테로환상 치환된페닐 메탄온

Also Published As

Publication number Publication date
CN106163520B (zh) 2019-12-13
TR201809598T4 (tr) 2018-07-23
WO2015165842A1 (en) 2015-11-05
US20170042888A1 (en) 2017-02-16
MA39927A (fr) 2017-03-08
RS57535B1 (sr) 2018-10-31
MA39927B1 (fr) 2018-09-28
SG11201608397UA (en) 2016-11-29
MY189930A (en) 2022-03-22
HRP20181205T1 (hr) 2018-09-21
EP3137073B1 (en) 2018-06-06
SG10201909382UA (en) 2019-11-28
JP6283766B2 (ja) 2018-02-21
EP3137073A1 (en) 2017-03-08
PH12016501784B1 (en) 2016-11-07
CY1120508T1 (el) 2019-07-10
JP2017511385A (ja) 2017-04-20
CN106163520A (zh) 2016-11-23
US9877963B2 (en) 2018-01-30
SI3137073T1 (sl) 2018-09-28
ES2683184T3 (es) 2018-09-25
PH12016501784A1 (en) 2016-11-07
AR100209A1 (es) 2016-09-21
KR20160130517A (ko) 2016-11-11
KR101869185B1 (ko) 2018-06-19

Similar Documents

Publication Publication Date Title
IL247841A0 (en) Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma
HK1243325A1 (zh) 用於治療視覺障礙的組合物和方法
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
HRP20181205T1 (hr) Glyt1 inhibitori za uporabu u liječenju hematoloških poremećaja
IL247589A0 (en) Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
IL247699A0 (en) Preparations and methods for the treatment of kidney disorders
IL251904A0 (en) Epilimod for use in the treatment of melanoma
PL3122349T3 (pl) Kompozycje do leczenia samotrawienia
IL263804A (en) Wnt inhibitors for use in the treatment of fibrosis
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
PT3093022T (pt) Inibidores gata-3 para utilização no tratamento de asma desencadeada por th2
IL251345B (en) Preparations for use in the treatment of peri-implantitis
IL246855A0 (en) Materials for use in the treatment of retinitis
HK1225994A1 (zh) 用於治療過敏性病症的組合物
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
IL248494A0 (en) Methods and compositions for the treatment of fat storage diseases
EP3200795A4 (en) Use of agents for treating fat-related disorders
ZA201408464B (en) Composition for the use in treatment of asthma